Genome & Co. has divulged antibody-drug conjugates consisting of antibodies targeting basal cell adhesion molecules (BCAM) covalently linked to a cytotoxic drug through a linker reported to be useful for the treatment of cancer.
Uppthera Inc. has identified proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to a serine/threonine-protein kinase PLK1 (STPK13)-targeting moiety reported to be useful for the treatment of cancer.
Arc Research Institute and Stanford University have disclosed ectonucleotide pyrophosphatase/phosphodiesterase family member 1 (ENPP1) and/or ENPP3 inhibitors reported to be useful for the treatment of cancer.
Investigators from Secarna Pharmaceuticals GmbH & Co. KG recently presented data for their antisense oligonucleotide (ASO) SECN-15 that targets and downregulates the expression of neuropilin-1 (NRP1), a transmembrane co-receptor that promotes tumor progression in several tumor types, including breast and gastric cancers.
Evidence suggests the composition of the gut microbiome modulates a tumor’s response to therapy. Maat Pharma SA has thus developed Microbiome Ecosystem Therapies (METs) that replicate, at a large scale, the effects of the gut microbiome in people who respond to immune checkpoint inhibitor (ICI) therapy.
Researchers from the Wuhan Institute of Virology and collaborating institutions aimed to shed light on the physiological role of mesothelin (MSLN) and to identify antibodies that directly inhibit its function in tumor progression.
Agora Open Science Trust’s wholly owned open science drug development company, M4K Pharma, has nominated M4K-2009 as the lead development candidate for diffuse intrinsic pontine glioma (DIPG). The ALK2 inhibitor program is now advancing into IND-enabling studies for this pediatric brain cancer.
GSK plc said in paperwork filed with the U.S. SEC that the potentially whopping deal inked in the summer of 2020 with Ideaya Biosciences Inc. has gone down the tubes.
Targeted therapies and immunotherapies continue to show better results than chemotherapy in investigator-initiated and company-sponsored cancer trials, and newer options demonstrate improvements over older ones, supporting potential shifts in how patients are treated.
RSS
